Journal Article

UK MS pregnancy register – A growing database

Rod, Middleton, Stella, Hughes, Katy, Murray, Ruth, Dobson, Owen, Pearson, David, Rog, Peter, Brex, Elaine, Craig, Chen, Liu, Helen, Ford

2023

Overview

IntroductionThe UK MS Pregnancy Register gathers pregnancy data in women with multiple sclerosis (MS) to address research gaps. We present data from >100 participants recruited since initiation in 2021.MethodsWomen with MS enter data via a dedicated online portal, completing questionnaires at 2 timepoints during pregnancy, and 3- and 12 months post-partum.ResultsOf 131 participants, most were White ethnicity (91%), and had relapsing-remitting MS (94%). 101 (89%) had ever taken DMT. Mean age at diagnosis and registration were 28.6 and 33.1 years respec- tively. Most registered in the first trimester of pregnancy (47.3%, n=62). Median EDSS was 2.5. 18 relapses were recorded in 15 patients; most relapses occurred in late pregnancy and postpartum. 78% discussed pregnancy in advance with their MS team. 86 pregnancies were exposed to DMT (62.3%), most commonly natalizumab (34.9%, n=30), glatiramer acetate (20.9%, n=18), and dimethyl fumarate (12.8%, n=11). 120 participants (91.6%) took supplements during pregnancy. Delivery gestation varied from 38 to 41 weeks, with the majority having delivered at 40 weeks. Postnatally, 58.3% of participants scored >10 on the Edinburgh PND scale.ConclusionSuch data demonstrates feasibility of large-scale, patient-orientated data gathering. Further work is required to improve postpartum data acquisition.

• Publisher: BMJ Publishing Group Ltd,BMJ Publishing Group LTD
• Subject: Association of British Neurologists: Annual Meeting Abstracts 2023 / Monoclonal antibodies / Pregnancy